LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Community-supported self-administered tuberculosis treatment combined with active tuberculosis screening: a pilot experience in Conakry, Guinea.

    Hassane-Harouna, Souleymane / Gils, Tinne / Decroo, Tom / Ortuño-Gutiérrez, Nimer / Delamou, Alexandre / Cherif, Gba-Foromo / Camara, Lansana Mady / Rigouts, Leen / de Jong, Bouke Catherine

    Global health action

    2023  Volume 16, Issue 1, Page(s) 2262134

    Abstract: Directly observed treatment (DOT) for tuberculosis (TB) is recommended by the World Health Organization. However, DOT does not always meet patients' preferences, burdens health facilities, and is hard to implement in settings where access to healthcare ... ...

    Abstract Directly observed treatment (DOT) for tuberculosis (TB) is recommended by the World Health Organization. However, DOT does not always meet patients' preferences, burdens health facilities, and is hard to implement in settings where access to healthcare services is regularly interrupted. A model addressing these limitations of DOT is community-supported self-administered treatment (CS-SAT), in which patients who self-administer TB treatment receive regular visits from community members. Guinea is a country with a high TB burden, recurrent epidemics, and periodic socio-political unrest. We piloted a CS-SAT model for drug-susceptible TB patients in Conakry, led by community volunteers, who also conducted active TB case finding among household contacts and referrals for isoniazid preventive treatment (IPT) in children below 5 years old. We aimed to assess TB treatment outcomes of patients on CS-SAT and describe the number of patients identified with TB case finding and IPT provision. Prospectively enrolled bacteriologically confirmed TB patients, presenting to two facilities, received monthly TB medication. Community volunteers performed bi-weekly (initiation phase) and later monthly (continuation phase) home visits to verify treatment adherence, screen household contacts for TB, and assess IPT uptake in children under five. Among 359 enrolled TB patients, 237 (66.0%) were male, and 37 (10.3%) were HIV-positive. Three hundred forty (94.7%) participants had treatment success, seven (1.9%) died, seven (1.9%) experienced treatment failure, and five (1.4%) were lost-to-follow-up. Among 1585 household contacts screened for TB, 26 (1.6%) had TB symptoms, of whom five (19.2%) were diagnosed with pulmonary TB. IPT referral was done for 376 children from 198 households. In a challenging setting, where DOT is often not feasible, CS-SAT led to successful TB treatment outcomes and created an opportunity for active TB case finding and IPT referral. We recommend the Guinean CS-SAT model for implementation in similar settings.
    MeSH term(s) Child ; Humans ; Male ; Child, Preschool ; Female ; Antitubercular Agents/therapeutic use ; Guinea ; Tuberculosis/diagnosis ; Tuberculosis/drug therapy ; Tuberculosis/epidemiology ; Isoniazid/therapeutic use ; Tuberculosis, Pulmonary/drug therapy
    Chemical Substances Antitubercular Agents ; Isoniazid (V83O1VOZ8L)
    Language English
    Publishing date 2023-10-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2540569-X
    ISSN 1654-9880 ; 1654-9880
    ISSN (online) 1654-9880
    ISSN 1654-9880
    DOI 10.1080/16549716.2023.2262134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Face mask sampling (FMS) for tuberculosis shows lower diagnostic sensitivity than sputum sampling in Guinea.

    Hassane-Harouna, Souleymane / Braet, Sofie Marijke / Decroo, Tom / Camara, Lansana Mady / Delamou, Alexandre / Bock, Sven de / Ortuño-Gutiérrez, Nimer / Cherif, Gba-Foromo / Williams, Caroline M / Wisniewska, Anika / Barer, Michael R / Rigouts, Leen / de Jong, Bouke Catherine

    Annals of clinical microbiology and antimicrobials

    2023  Volume 22, Issue 1, Page(s) 81

    Abstract: Background: Pulmonary tuberculosis (PTB) diagnosis relies on sputum examination, a challenge in sputum-scarce patients. Alternative non-invasive sampling methods such as face mask sampling (FMS) have been proposed.: Objective: To evaluate the value ... ...

    Abstract Background: Pulmonary tuberculosis (PTB) diagnosis relies on sputum examination, a challenge in sputum-scarce patients. Alternative non-invasive sampling methods such as face mask sampling (FMS) have been proposed.
    Objective: To evaluate the value of FMS for PTB diagnosis by assessing its agreement with sputum samples processed by GeneXpert MTB/RIF (Ultra)(Xpert) testing, and describe FMS sensitivity and specificity.
    Methods: This was a prospective study conducted at the Carrière TB clinic in Guinea. Presumptive TB patients willing to participate were asked to wear a surgical mask containing a polyvinyl alcohol (PVA) strip for thirty minutes. Subsequently, two spot sputum samples were collected, of which one was processed by microscopy on site and the other by Xpert in Guinea's National Reference Laboratory of Mycobacteriology (LNRM). The first 30 FMS were processed at the Supranational Reference Laboratory in Antwerp, Belgium, and the following 118 FMS in the LNRM.
    Results: One hundred fifty patients participated, of whom 148 had valid results for both mask and sputum. Sputum smear microscopy was positive for 47 (31.8%) patients while sputum-Xpert detected MTB in 54 (36.5%) patients. Among the 54 patients testing sputum-Xpert positive, 26 (48.1%) yielded a positive FMS-Xpert result, while four sputum-Xpert negative patients tested positive for FMS and 90 patients were Xpert-negative for both sputum and mask samples, suggesting a moderate level of agreement (k-value of 0.47). The overall mask sensitivity was 48.1%, with 95.7% specificity.
    Conclusion: In our setting, Xpert testing on FMS did not yield a high level of agreement to sputum sample.
    MeSH term(s) Humans ; Sputum ; Guinea ; Masks ; Prospective Studies ; Tuberculosis ; Tuberculosis, Pulmonary/diagnosis
    Language English
    Publishing date 2023-09-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 2097873-X
    ISSN 1476-0711 ; 1476-0711
    ISSN (online) 1476-0711
    ISSN 1476-0711
    DOI 10.1186/s12941-023-00633-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.

    Hassane-Harouna, Souleymane / Cherif, Gba-Foromo / Ortuno-Gutierrez, Nimer / Cisse, Diao / Camara, Lansana Mady / Diallo, Boubacar Djelo / Camara, Souleymane / Bangoura, Adama Marie / Lynen, Lutgarde / Decroo, Tom

    PloS one

    2020  Volume 15, Issue 8, Page(s) e0237355

    Abstract: Setting: Since August 2016, after the Ebola outbreak, the Guinean National Tuberculosis Programme and Damien Foundation implemented the shorter treatment regimen (STR) for multidrug-resistant tuberculosis (MDR-TB) in the three MDR-TB sites of Conakry. ... ...

    Abstract Setting: Since August 2016, after the Ebola outbreak, the Guinean National Tuberculosis Programme and Damien Foundation implemented the shorter treatment regimen (STR) for multidrug-resistant tuberculosis (MDR-TB) in the three MDR-TB sites of Conakry. Previously, the longer regimen was used to treat MDR-TB.
    Objectives: In a post-Ebola context, with a weakened health system, we describe the MDR-TB treatment uptake, patients characteristics, treatment outcomes and estimate the effect of using the longer versus STR on having a programmatically adverse outcome.
    Design: This is a retrospective cohort study in RR-TB patients treated with either the longer regimen or STR.
    Results: In Conakry, in 2016 and 2017, 131 and 219 patients were diagnosed with rifampicin-resistant tuberculosis (RR-TB); and 108 and 163 started treatment, respectively. Of 271 patients who started treatment, 75 were treated with the longer regimen and 196 with the STR. Patients characteristics were similar regardless of the regimen except that the median age was higher among those treated with a longer regimen (30 years (IQR:24-38) versus 26 years (IQR:21-39) for the STR. Patients treated with a STR were more likely to obtain a programmatically favorable outcome (74.0% vs 58.7%, p = 0.01) as lost to follow up was higher among those treated with a longer regimen (20.0% vs 8.2%, p = 0.006). Patients on a longer regimen were more than 2 times more likely (aOR: 2.5; 95%CI:1.3,4.7) to have a programmatically adverse outcome as well as being 45 years or older (aOR: 2.8; 95%CI:1.3,6.2), HIV positive (aOR:3.3; 95%CI:1.6,6.6) and attendance at a clinic without NGO support (aOR:3.0; 95%:1.6,5.7).
    Conclusion: In Guinea, patients treated with the STR were more likely to have a successful outcome than those treated with the longer MDR-TB treatment regimen. Lost to follow-up was higher in patients on the longer regimen. However, STR treatment outcomes were less good than those reported in the region.
    MeSH term(s) Adolescent ; Adult ; Antitubercular Agents/therapeutic use ; Child ; Child, Preschool ; Cohort Studies ; Female ; Guinea ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/drug therapy ; Young Adult
    Chemical Substances Antitubercular Agents
    Language English
    Publishing date 2020-08-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0237355
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family.

    Ejo, Mebrat / Hassane-Harouna, Souleymane / Souleymane, Mahamadou Bassirou / Lempens, Pauline / Dockx, Jeroen / Uwizeye, Cecile / De Rijk, Pim / Decroo, Tom / Diro, Ermias / Torrea, Gabriela / Rigouts, Leen / Piubello, Alberto / de Jong, Bouke C

    Tuberculosis (Edinburgh, Scotland)

    2020  Volume 122, Page(s) 101922

    Abstract: In this study, we analyzed the M. tuberculosis complex (MTBc) population structure among multidrug-resistant TB (MDR-TB) patients in Niger and tested whether the Cameroon family displayed a slower response to MDR-TB treatment. We genotyped baseline ... ...

    Abstract In this study, we analyzed the M. tuberculosis complex (MTBc) population structure among multidrug-resistant TB (MDR-TB) patients in Niger and tested whether the Cameroon family displayed a slower response to MDR-TB treatment. We genotyped baseline clinical isolates that had been collected from pulmonary MDR-TB patients recruited consecutively between 2008 and 2016 in Niger. Spoligotyping was used to analyze the genetic diversity of mycobacterial lineages, and Kaplan Meier's analysis to compare treatment outcomes. A total of 222 MTBc isolates were genotyped; 204 (91,9%) were identified as the Euro-American L4 lineage, with the Ghana family (106, 47,4%) and the Cameroon family (63, 28,4%) being predominant. Patients infected by Cameroon family isolates 61(96,8%) showed faster conversion (log-rank p < 0.01) than those infected with Ghana family isolates (91,5%), and were more likely to experience favorable outcome (adjusted odds ratio [aOR] 4.4; 95%CI 1.1-17.9]; p = 0.015). We found no association between MTBc families and second-line drug resistance profiles (p > 0.05). Our findings show that MDR-TB in Niger is caused by major spoligotypes of the Euro-American L4; with more rapid smear and culture conversion in patients infected with the Cameroon family. These first insights may alert clinicians that slow conversion may be associated with the type of infecting strain.
    MeSH term(s) African Continental Ancestry Group ; Antitubercular Agents/therapeutic use ; Bacteriological Techniques ; Cameroon/ethnology ; Genotype ; Ghana/ethnology ; Humans ; Mycobacterium tuberculosis/drug effects ; Mycobacterium tuberculosis/genetics ; Mycobacterium tuberculosis/pathogenicity ; Niger/epidemiology ; Registries ; Sputum/microbiology ; Time Factors ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/diagnosis ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/ethnology ; Tuberculosis, Multidrug-Resistant/microbiology ; Tuberculosis, Pulmonary/diagnosis ; Tuberculosis, Pulmonary/drug therapy ; Tuberculosis, Pulmonary/ethnology ; Tuberculosis, Pulmonary/microbiology
    Chemical Substances Antitubercular Agents
    Language English
    Publishing date 2020-03-26
    Publishing country Scotland
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2046804-0
    ISSN 1873-281X ; 1472-9792
    ISSN (online) 1873-281X
    ISSN 1472-9792
    DOI 10.1016/j.tube.2020.101922
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.

    Souleymane, Mahamadou Bassirou / Piubello, Alberto / Lawan, Ibrahim Mamane / Hassane-Harouna, Souleymane / Assao-Neino, Mourtala Mohamed / Soumana, Alphazazi / Hamidou-Harouna, Zelika / Gagara-Issoufou, Assiatou / Ortuño-Gutiérrez, Nimer / Roggi, Alberto / Schwoebel, Valerie / Mamadou, Saïdou / Lynen, Lutgarde / De Jong, Bouke / Van Deun, Armand / Decroo, Tom

    The European respiratory journal

    2021  Volume 57, Issue 1

    Abstract: The short treatment regimen (STR) achieves a >80% cure in rifampicin-resistant tuberculosis (RR-TB) patients. However, ototoxicity induced by the injectable is a concern. This is the first study to evaluate the replacement of injectables by linezolid in ... ...

    Abstract The short treatment regimen (STR) achieves a >80% cure in rifampicin-resistant tuberculosis (RR-TB) patients. However, ototoxicity induced by the injectable is a concern. This is the first study to evaluate the replacement of injectables by linezolid in patients with audiometry abnormalities at baseline or during the treatment.We conducted a retrospective cohort study of all RR-TB patients started on the STR between 2016 and June, 2019, in Niger. Patients underwent audiometry every 2 months in 2016 and every month since 2017.Of 195 patients, 16.9% (33 out of 195) received linezolid from the start (n=17), or switched from injectables to linezolid during treatment (n=16), based on audiometry abnormalities. In 2016, two patients developed severe ototoxicity despite switching to linezolid. Since 2017, no patient developed severe hearing loss or complete deafness. Severe haematological toxicity was observed in 18.1% (six out of 33) of patients on linezolid, none of which was life threatening. The use of linezolid was associated with severe but manageable adverse events (hazard ratio 8.9, 95% CI 2.5-31.5; p=0.001). A total of 90.9% (30 out of 33) of patients on a linezolid-containing STR were cured, and none experienced treatment failure. Three died, but not due to adverse events.Baseline and monthly audiometry monitoring and using linezolid after detection of hearing abnormalities appears effective to prevent severe ototoxicity, while keeping high treatment success and manageable adverse events.
    MeSH term(s) Antitubercular Agents/adverse effects ; Deafness/drug therapy ; Hearing Loss/chemically induced ; Hearing Loss/prevention & control ; Humans ; Linezolid/adverse effects ; Ototoxicity ; Retrospective Studies ; Rifampin/adverse effects ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/drug therapy
    Chemical Substances Antitubercular Agents ; Linezolid (ISQ9I6J12J) ; Rifampin (VJT6J7R4TR)
    Language English
    Publishing date 2021-01-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.02250-2020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.

    Piubello, Alberto / Souleymane, Mahamadou Bassirou / Hassane-Harouna, Souleymane / Yacouba, Abdourahamane / Lempens, Pauline / Assao-Neino, Mourtala Mohamed / Maman-Lawan, Ibrahim / Attaher, Sala / Moustapha, Boubacar / Soumana, Alphazazi / Gagara-Issoufou, Assiatou / Ortuño-Gutiérrez, Nimer / Roggi, Alberto / Gumusboga, Mourad / Hamidou-Harouna, Zelika / Dockx, Jeroen / Mamadou, Saïdou / de Jong, Bouke C / Decroo, Tom /
    Van Deun, Armand

    Respiratory medicine

    2019  Volume 161, Page(s) 105844

    Abstract: Background: In Niger, the Shorter Treatment Regimen (STR) has been implemented nationwide for rifampicin resistant tuberculosis (RR-TB), since 2008. No previous publication has shown the results from countrywide programmatic implementation using few ... ...

    Abstract Background: In Niger, the Shorter Treatment Regimen (STR) has been implemented nationwide for rifampicin resistant tuberculosis (RR-TB), since 2008. No previous publication has shown the results from countrywide programmatic implementation using few exclusion criteria, nor exhaustively assessed the effect of initial resistance to companion drugs on outcomes.
    Methods: The National Tuberculosis Programme and the Damien Foundation conducted a retrospective observational study to evaluate the management of RR-TB from 2008 to 2016. Baseline resistance to drugs was assessed phenotypically, complemented by screening the inhA, katG and pncA genes. Cured patients were followed-up for a period of one year after cure.
    Findings: Among 1044 patients tested for rifampicin resistance, mainly previously treated patients, 332 were diagnosed with pulmonary RR/TB, 288 were enrolled on treatment and 255 started on STR. Six patients received a modified STR. Among 249 patients on standardised STR, 207 (83·1%) were cured relapse-free, eight (3·2%) had failure, 23 (9·2%) died, seven (2·8%) were lost to follow-up and four (1·6%) relapsed. The risk of unfavourable outcome was higher in patients with initial resistance to fluoroquinolones (aOR 20·4, 95%CI:5·6-74·6) and very severely underweight (aOR 3·9, 95%CI:1·5-10·1). Successful outcome was not affected by initial resistance to companion drugs. Serious ototoxicity was reported in eight patients (3·2%).
    Interpretation: A comprehensive nationwide approach to multidrug-resistant tuberculosis management using the STR was feasible and successful. Outcomes were not affected by initial resistance to companion drugs. Our study confirms the effectiveness and safety of the STR.
    Funding: Damien Foundation and Institute of Tropical Medicine-Antwerp.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antitubercular Agents/administration & dosage ; Communicable Disease Control ; Drug Resistance, Multiple, Bacterial/genetics ; Feasibility Studies ; Female ; Fluoroquinolones ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Niger ; Rifampin ; Tuberculosis, Multidrug-Resistant/drug therapy ; Young Adult
    Chemical Substances Antitubercular Agents ; Fluoroquinolones ; Rifampin (VJT6J7R4TR)
    Language English
    Publishing date 2019-11-23
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2019.105844
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.

    Casco, Nicolas / Jorge, Alberto Levi / Palmero, Domingo Juan / Alffenaar, Jan-Willem / Fox, Greg J / Ezz, Wafaa / Cho, Jin-Gun / Denholm, Justin / Skrahina, Alena / Solodovnikova, Varvara / Arbex, Marcos Abdo / Alves, Tatiana / Rabahi, Marcelo Fouad / Pereira, Giovana Rodrigues / Sales, Roberta / Silva, Denise Rossato / Saffie, Muntasir M / Salinas, Nadia Escobar / Miranda, Ruth Caamaño /
    Cisterna, Catalina / Concha, Clorinda / Fernandez, Israel / Villalón, Claudia / Vera, Carolina Guajardo / Tapia, Patricia Gallegos / Cancino, Viviana / Carbonell, Monica / Cruz, Arturo / Muñoz, Eduardo / Muñoz, Camila / Navarro, Indira / Pizarro, Rolando / Cristina Sánchez, Gloria Pereira / Vergara Riquelme, Maria Soledad / Vilca, Evelyn / Soto, Aline / Flores, Ximena / Garavagno, Ana / Bahamondes, Martina Hartwig / Merino, Luis Moyano / Pradenas, Ana María / Revillot, Macarena Espinoza / Rodriguez, Patricia / Salinas, Angeles Serrano / Taiba, Carolina / Valdés, Joaquín Farías / Subiabre, Jorge Navarro / Ortega, Carlos / Palma, Sofia / Castillo, Patricia Perez / Pinto, Mónica / Bidegain, Francisco Rivas / Venegas, Margarita / Yucra, Edith / Li, Yang / Cruz, Andres / Guelvez, Beatriz / Victoria Plaza, Regina / Tello Hoyos, Kelly Yoana / Cardoso-Landivar, José / Van Den Boom, Martin / Andréjak, Claire / Blanc, François-Xavier / Dourmane, Samir / Froissart, Antoine / Izadifar, Armine / Rivière, Frédéric / Schlemmer, Frédéric / Manika, Katerina / Diallo, Boubacar Djelo / Hassane-Harouna, Souleymane / Artiles, Norma / Mejia, Licenciada Andrea / Gupta, Nitesh / Ish, Pranav / Mishra, Gyanshankar / Patel, Jigneshkumar M / Singla, Rupak / Udwadia, Zarir F / Alladio, Francesca / Angeli, Fabio / Calcagno, Andrea / Centis, Rosella / Codecasa, Luigi Ruffo / De Lauretis, Angelo / Esposito, Susanna M R / Formenti, Beatrice / Gaviraghi, Alberto / Giacomet, Vania / Goletti, Delia / Gualano, Gina / Matteelli, Alberto / Migliori, Giovanni Battista / Motta, Ilaria / Palmieri, Fabrizio / Pontali, Emanuele / Prestileo, Tullio / Riccardi, Niccolò / Saderi, Laura / Saporiti, Matteo / Sotgiu, Giovanni / Spanevello, Antonio / Stochino, Claudia / Tadolini, Marina / Torre, Alessandro / Villa, Simone / Visca, Dina / Kurhasani, Xhevat / Furjani, Mohammed / Rasheed, Najia / Danila, Edvardas / Diktanas, Saulius / Ridaura, Ruy López / Luna López, Fátima Leticia / Torrico, Marcela Muñoz / Rendon, Adrian / Akkerman, Onno W / Chizaram, Onyeaghala / Al-Abri, Seif / Alyaquobi, Fatma / Althohli, Khalsa / Aguirre, Sarita / Teixeira, Rosarito Coronel / De Egea, Viviana / Irala, Sandra / Medina, Angélica / Sequera, Guillermo / Sosa, Natalia / Vázquez, Fátima / Llanos-Tejada, Félix K / Manga, Selene / Villanueva-Villegas, Renzo / Araujo, David / Sales Marques, Raquel DuarteTânia / Socaci, Adriana / Barkanova, Olga / Bogorodskaya, Maria / Borisov, Sergey / Mariandyshev, Andrei / Kaluzhenina, Anna / Vukicevic, Tatjana Adzic / Stosic, Maja / Beh, Darius / Ng, Deborah / Ong, Catherine W M / Solovic, Ivan / Dheda, Keertan / Gina, Phindile / Caminero, José A / De Souza Galvão, Maria Luiza / Dominguez-Castellano, Angel / García-García, José-María / Pinargote, Israel Molina / Fernandez, Sarai Quirós / Sánchez-Montalvá, Adrián / Huguet, Eva Tabernero / Murguiondo, Miguel Zabaleta / Bart, Pierre-Alexandre / Mazza-Stalder, Jesica / D'Ambrosio, Lia / Kamolwat, Phalin / Bakko, Freya / Barnacle, James / Bird, Sophie / Brown, Annabel / Chandran, Shruthi / Killington, Kieran / Man, Kathy / Papineni, Padmasayee / Ritchie, Flora / Tiberi, Simon / Utjesanovic, Natasa / Zenner, Dominik / Hearn, Jasie L / Heysell, Scott / Young, Laura

    The European respiratory journal

    2023  Volume 62, Issue 5

    Abstract: Background: Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19.: Methods: We collected data from ...

    Abstract Background: Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19.
    Methods: We collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end of cohort time. All patients had TB and COVID-19; for analysis purposes, deaths were attributed to TB, COVID-19 or both. Survival analysis was performed using Cox proportional risk-regression models, and the log-rank test was used to compare survival and mortality attributed to TB, COVID-19 or both.
    Results: Overall, 788 patients with COVID-19 and TB (active or sequelae) were recruited from 31 countries, and 10.8% (n=85) died during the observation period. Survival was significantly lower among patients whose death was attributed to TB and COVID-19
    Conclusions: In our global cohort, death was the outcome in >10% of patients with TB and COVID-19. A range of demographic and clinical predictors are associated with adverse outcomes.
    MeSH term(s) Humans ; Male ; COVID-19/complications ; HIV Infections/complications ; Coinfection ; Risk Factors ; Tuberculosis, Miliary ; Retrospective Studies
    Language English
    Publishing date 2023-11-29
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.00925-2023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top